-
公开(公告)号：EP2175873B1
公开(公告)日：2015-11-11
申请号：EP08772390.4
申请日：2008-07-02
申请人： NoNO Inc.
发明人： TASKER, Andrew , DOUCETTE, Tracy , TYMIANSKI, Michael , MENDOZA, Kenneth , BELMARES, Michael, P. , GARMAN, David , LU, Peter, S.
CPC分类号： A61K38/1787 , A61K38/07
-
2.发明授权
公开(公告)号：EP2229185B1
公开(公告)日：2015-10-07
申请号：EP08859906.3
申请日：2008-12-02
申请人： NoNO Inc.
IPC分类号： A61K47/42
CPC分类号： A61K38/1787 , A61K9/0019 , A61K31/56 , A61K38/08 , A61K45/06 , A61K47/645 , A61K2300/00
-
公开(公告)号：EP2723363A2
公开(公告)日：2014-04-30
申请号：EP12802409.8
申请日：2012-06-23
申请人： NoNO Inc.
发明人： TYMIANSKI, Michael
CPC分类号： A61K38/10 , A61K38/1787 , A61K38/49 , A61K2300/00
摘要： The invention provides a combination treatment for ischemia conditions in or otherwise affecting the CNS, such as stroke. The treatment involves administration of a PSD-95 inhibitor and performing reperfusion therapy (e.g., by administration of tPA). Administering a PSD-95 inhibitor in combination with reperfusion therapy increases the efficacy of the reperfusion therapy and/or slows the decline in efficacy of reperfusion therapy with time after onset of ischemia thus extending the window in which reperfusion therapy can be administered.
-
4.发明公开CO-ADMINISTRATION OF AN AGENT LINKED TO AN INTERNALIZATION PEPTIDE WITH AN ANTI-INFLAMMATORY 有权意味着同时给药以A内在TAT肽相连，抗炎剂
公开(公告)号：EP2229185A2
公开(公告)日：2010-09-22
申请号：EP08859906.3
申请日：2008-12-02
申请人： Nono, Inc. , Arbor Vita Corporation
IPC分类号： A61K47/42
CPC分类号： A61K38/1787 , A61K9/0019 , A61K31/56 , A61K38/08 , A61K45/06 , A61K47/645 , A61K2300/00
摘要： The invention provides methods of delivering pharmacologic agents linked to an internalization peptide, in which an inflammatory response inducible by the internalization peptide is inhibited by co-administration of an anti-inflammatory or by linking the internalization peptide to biotin or similar molecule. Such methods are premised in part on the results described in the examples whereby administration of a pharmacological agent linked to tat at high dosages is closely followed by an inflammatory response, which includes mast cell degranulation, histamine release and the typical sequelae of histamine release, such as redness, heat, swelling, and hypotension.
-
5.发明公开
公开(公告)号：EP1713499A4
公开(公告)日：2009-06-10
申请号：EP04802294
申请日：2004-12-13
申请人： UNIV MANITOBA
发明人： JAMIESON JAMES , THORNE-TJOMSLAND GRO , YAO ZEMIN , MARAT ANDREA , TRAN KHAI
CPC分类号： G01N33/92 , A61K38/1709 , A61K38/177 , A61K38/1787 , A61K38/45 , G01N33/5076 , G01N2800/044
摘要： The invention provides uses of autophagocytosis inducing compounds for reducing serum levels of triglycerides and VLDL and the preparation of medicaments. The invention also provides the use of autophagocytosis inducing compounds for treating hypertriglyceridemia, hyperlipidemia, hypercholesterolemia, hyperlipoproteinemia, atherosclerosis, arteriosclerosis, peripheral artery disease, coronary artery disease, congestive heart failure, myocardial ischemia, myocardial infarction, ischemic stroke, hemorrhagic stroke, or diabetes, insulin resistance, hemodialysis, glycogen storage disease type I, polycystic ovary syndrome, combination thereof. The invention further provides methods of identifying compounds which modulate autophagocytosis.
-
6.发明公开
公开(公告)号：EP1713499A1
公开(公告)日：2006-10-25
申请号：EP04802294.1
申请日：2004-12-13
CPC分类号： G01N33/92 , A61K38/1709 , A61K38/177 , A61K38/1787 , A61K38/45 , G01N33/5076 , G01N2800/044
摘要： The invention provides uses of autophagocytosis inducing compounds for reducing serum levels of triglycerides and VLDL and the preparation of medicaments. The invention also provides the use of autophagocytosis inducing compounds for treating hypertriglyceridemia, hyperlipidemia, hypercholesterolemia, hyperlipoproteinemia, atherosclerosis, arteriosclerosis, peripheral artery disease, coronary artery disease, congestive heart failure, myocardial ischemia, myocardial infarction, ischemic stroke, hemorrhagic stroke, or diabetes, insulin resistance, hemodialysis, glycogen storage disease type I, polycystic ovary syndrome, combination thereof. The invention further provides methods of identifying compounds which modulate autophagocytosis.
-
公开(公告)号：EP2841063A2
公开(公告)日：2015-03-04
申请号：EP13720734.6
申请日：2013-04-26
发明人： SHEKHAR, Anantha , LAI, Yvonne
IPC分类号： A61K31/191 , A61K31/196 , A61K31/4192 , A61P25/00
CPC分类号： C07K14/47 , A61K31/191 , A61K31/196 , A61K31/4192 , A61K31/445 , A61K31/606 , A61K38/162 , A61K38/1787 , C07K5/1019 , C07K5/1021 , C07K7/06
摘要： The invention described herein pertains to compositions and methods for treating PTSD and related diseases. In particular, the invention described herein pertains to compositions and methods for treating PTSD and related diseases by administering modulators of NMDA NR2-PSD95-nNOS signaling.
摘要翻译： 在本发明中涉及组合物和方法描述了用于治疗创伤后应激障碍和相关疾病。 特别是，在本发明中涉及的组合物和方法描述了通过施用NMDA NR2 PSD95-nNOS的信令的调制器治疗PTSD和相关疾病。
-
公开(公告)号：EP2786766A1
公开(公告)日：2014-10-08
申请号：EP13162532.9
申请日：2013-04-05
申请人： Ufpeptides S.r.l.
CPC分类号： A61K47/55 , A61K38/1787 , A61K47/543 , A61K47/545 , C07D403/14
摘要： The invention relates to a supramolecular aggregate of formula (I) wherein A is an active substance, n is an integer from 4 to 16 and X is a core having at least four binding amino group. In a preferred embodiment the maleimido-funzionalized core X is selected from PWT1, PWT2 and PWT3. The supramolecular aggregates can be used in the field of drugs, vaccines, as ligands for GPCR, i.e. agonists as well as antagonist, as antibiotics and as diagnostics eventually in complex with radionuclides.
摘要翻译： 本发明涉及式（I）的超分子聚集体，其中A为活性物质，n为4至16的整数，X为具有至少4个结合氨基的核心。 在优选的实施方案中，马来酰亚胺基化的核心X选自PWT1，PWT2和PWT3。 超分子聚集体可用于药物，疫苗，GPCR的配体，即激动剂以及拮抗剂，作为抗生素，以及最终与放射性核素复合的诊断领域。
-
公开(公告)号：EP2770992A1
公开(公告)日：2014-09-03
申请号：EP12844191.2
申请日：2012-10-25
申请人： Stein, Emily A. , Swanson, Christina D. , Evans, Michael A. , Venkateswara-Rao, Kondapavulur T.
发明人： Stein, Emily A. , Swanson, Christina D. , Evans, Michael A. , Venkateswara-Rao, Kondapavulur T.
IPC分类号： A61K31/401 , A61K31/405 , A61K31/704 , A61P9/02
CPC分类号： A61K31/7048 , A61K9/0012 , A61K31/401 , A61K31/405 , A61K31/4166 , A61K31/55 , A61K33/14 , A61K38/1787 , A61K45/06 , A61M25/0084 , A61M25/10 , A61M2025/0086 , A61M2025/1093 , A61K2300/00
摘要： Agents, methods, and devices for affecting nerve function are described. One embodiment of an agent includes a cardiac glycoside, an ACE inhibitor, and an NSAID. The agent may be delivered locally in a site-specific manner to a targeted nerve or portion of a nerve. For example, the agent may be delivered locally to the renal nerves to impair their function and treat hypertension. One embodiment of a delivery device includes one or more needle housings supported by a balloon. A delivery needle is slidably disposed within a needle lumen of each needle housing.
-
公开(公告)号：EP2049129B1
公开(公告)日：2013-06-12
申请号：EP07736477.6
申请日：2007-06-19
发明人： LAPIDOT, Tsvee , SPIEGEL, Asaf , RUBINSTEIN, Menachem , KALINKOVICH, Alexander , SHIVTIEL, Shoham
IPC分类号： A61K31/00
CPC分类号： A61K45/06 , A61K31/137 , A61K31/428 , A61K31/473 , A61K31/496 , A61K31/55 , A61K35/28 , A61K38/1787 , A61K38/193 , C12N5/0647 , C12N2501/22 , C12N2501/80 , C12N2501/81 , C12N2501/815 , A61K2300/00
-
-
-
-
-
-
-
-
-
搜索结果
47 条记录 (耗时 0.025 秒)
